← 產業報告目錄

Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide Tetraxetan, (Lu-177)- PNT2002, Radium-223 dichloride), Target (PSMA, SSTR, Bone Metastases), Indication (Prostate Cancer, Neuroendocrine Tumors (NETS), SCLC) - Global Forecast to 2035

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-09-13頁數 313報告編號 PH9552

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global radioligand therapy market is projected to reach USD 10.91 billion by 2035 from an estimated USD 3.15 billion in 2025, at a CAGR of 13.2% during the forecast period. The growth of the radioligand therapy market is majorly driven by increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, rising adoption of PSMA and SSTR PET imaging for patient selection, and expanding reimbursement coverage supporting broader patient access. By target, the prostate-specific membrane antigen segment accounted for the largest market share in 2024. Based on target, the market is categorized into Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), and other targets. The Prostate-Specific Membrane Antigen (PSMA) segment accounted for the largest share of the market in 2024. The large share of this segment is attributed to its high expression in prostate cancer cells and its minimal presence in normal tissues. This makes PSMA an ideal biomarker for precision oncology, enabling accurate patient selection and effective therapy delivery. The success of PSMA-targeted treatments, such as Pluvicto (lutetium-177 vipivotide tetraxetan), has reinforced its dominance, particularly in metastatic castration-resistant prostate cancer (mCRPC). By product, the Lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market in 2024. By product, the market is segmented into Lutetium‑177 Vipivotide Tetraxetan, Lutetium-177 Dotatate, Radium-223 Dichloride, [LU-177]-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU Rosopatamab Tetraxetan), Alphamedix (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products. In 2024, the lutetium-177 vipivotide tetraxetan segment accounted for the largest share of the market. Developed and commercialized by Novartis, Lutetium-177 vipivotide tetraxetan (Pluvicto) targets Prostate-Specific Membrane Antigen (PSMA), a protein highly expressed in prostate cancer cells, making it a precision therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). Since its FDA and EMA approvals, the therapy has become widely adopted due to its ability to extend survival and improve quality of life in patients with limited treatment options. Its use of lutetium-177 enables targeted beta radiation delivery, sparing surrounding healthy tissues while maximizing tumor control. By region, the Asia Pacific market is projected to grow at the highest CAGR during the forecast period. The market is segmented by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to grow at the highest CAGR during the forecast period. The key factors contributing to market growth include the rising cancer incidence, improvements in healthcare infrastructure, and increasing awareness of precision oncology solutions. Countries such as China, Japan, South Korea, India, and Australia are witnessing the growing adoption of nuclear medicine, which is supported by expanding diagnostic capabilities and investments in theragnostic. Governments & private institutions are actively investing in isotope production facilities, addressing long-standing supply challenges for key isotopes like lutetium-177 and actinium-225, essential for commercialized and pipeline RLT products. Regulatory authorities in the region also show greater receptivity to radiopharmaceutical approvals, creating a favourable environment for clinical development and faster patient access. The primary interviews conducted for this report can be categorized as follows: • By Respondent: Supply Side- 70% and Demand Side- 30% • By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25% • By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5% Key Companies The key players in the radioligand therapy market include Novartis AG (Switzerland), Bayer AG (Germany), Curium US LLC (US), Eli Lilly and Company (US), AstraZeneca plc (UK), Progenics Pharmaceuticals, Inc. (US), Ariceum Therapeutics GmbH (Germany), Telix Pharmaceuticals Limited (Australia), ITM Isotope Technologies Munich SE (Germany), Convergent Therapeutics, Inc. (US), Orano Med SAS (France), Actinium Pharmaceuticals, Inc. (US), Perspective Therapeutics, Inc. (US), Clarity Pharmaceuticals Ltd. (Australia), and Radiopharm Theranostics Ltd. (Australia), among others. Research Coverage This research report categorizes the radioligand therapy market, by product [Lutetium-177 vipivotide tetraxetan, LUTETIUM-177 DOTATATE, Radium-223 dichloride, (LU-177)-PNT2002, 225AC-PSMA-617, FPI-2265/ 225 AC PSMA – I&T, I-131-1095, TLX591 (177LU ROSOPATAMAB TETRAXETAN), ALPHAMEDIX (²¹²PB-DOTAMTATE), 67CU‑SAR‑BISPSMA, and other products), target (PSMA, SSTR, and other targets), indication (prostate cancer, neuroendocrine tumors, and other indications), and end user (tertiary care academic/comprehensive cancer centers, specialized nuclear medicine centers, and other end user), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa). The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the radioligand therapy market. A thorough analysis of the key industry players has provided insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements: new approvals/launches, collaborations, acquisitions, and recent developments associated with the radioligand therapy market. Reasons to buy this report The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the radioligand therapy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (increasing approvals and label expansions of RLT products, manufacturing scale-up, particularly for Lu-177 supply, the rising adoption of PSMA and SSTR PET imaging for patient selection. Expanding reimbursement coverage supporting broader patient access), restraints (Isotope scarcity for Lu-177 and Ac-225 creating supply bottlenecks, complex regulatory requirements for handling & licensing radioactive materials, logistical hurdles & half-life constraints limiting distribution), opportunities [advancements of alpha therapies (Ac-225, Pb-212) with strong clinical potential, expansion into earlier-line and adjuvant use, broadening eligible populations, combination regimens with immuno-oncology, PARP inhibitors, and other targeted agents), and challenges (reactor outages and geopolitical risks impacting isotope production & supply chains and the growing competition from alternative modalities such as ADCs and bispecific antibodies) • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the radioligand therapy market • Market Development: Comprehensive information about lucrative markets across varied regions • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the radioligand therapy market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment & funding activities, brand/product comparative analysis, and vendor valuation & financial metrics of the radioligand therapy market.
目錄 Table of Contents
1 INTRODUCTION 31 1.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 31 1.3 STUDY SCOPE 32 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 32 1.3.2 INCLUSIONS AND EXCLUSIONS 33 1.3.3 YEARS CONSIDERED 33 1.4 CURRENCY CONSIDERED 34 1.5 STAKEHOLDERS 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 2.1.1 SECONDARY DATA 36 2.1.1.1 Objectives of secondary research 36 2.1.1.2 Key data from secondary sources 37 2.1.2 PRIMARY DATA 37 2.1.2.1 Breakdown of primaries 38 2.1.2.2 Key objectives of primary research 38 2.2 MARKET SIZE ESTIMATION 39 2.2.1 GLOBAL MARKET ESTIMATION 39 2.2.1.1 Company revenue analysis (Bottom-up approach) 39 2.2.1.2 Revenue share analysis 40 2.2.1.3 MnM repository analysis 41 2.2.1.4 Primary interviews 41 2.2.2 INSIGHTS FROM PRIMARY EXPERTS 42 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 42 2.3 GROWTH RATE PROJECTIONS 44 2.4 DATA TRIANGULATION 46 2.5 RESEARCH ASSUMPTIONS 47 2.6 RESEARCH LIMITATIONS 47 2.7 RISK ANALYSIS 48 3 EXECUTIVE SUMMARY 49 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS 49 3.1.1 BIOTECH STARTUPS AND INNOVATIVE COMPANIES 49 3.1.2 ESTABLISHED MARKET LEADERS 50 3.1.3 CDMOS AND CROS 50   4 PREMIUM INSIGHTS 55 4.1 RADIOLIGAND THERAPY MARKET OVERVIEW 55 4.2 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT AND COUNTRY, 2025 56 4.3 RADIOLIGAND THERAPY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 57 4.4 RADIOLIGAND THERAPY MARKET: EMERGING VS. DEVELOPED MARKETS 58 4.5 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 58 4.6 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT 59 4.7 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE 59 4.8 REGULATORY POLICY INITIATIVES 60 5 MARKET OVERVIEW 61 5.1 INTRODUCTION 61 5.2 MARKET DYNAMICS 61 5.2.1 DRIVERS 62 5.2.1.1 Increasing approvals and label expansion of RLT products 62 5.2.1.2 Manufacturing scale-up of Lu-177 63 5.2.1.3 Rising adoption of prostate-specific membrane antigen and somatostatin receptor PET imaging 63 5.2.1.4 Expanding reimbursement coverage 63 5.2.2 RESTRAINTS 64 5.2.2.1 Isotope supply scarcity 64 5.2.2.2 Stringent regulatory requirements 64 5.2.2.3 Logistical hurdles and half-life constraints 64 5.2.3 OPPORTUNITIES 65 5.2.3.1 Advancements in alpha therapies 65 5.2.3.2 Expansion of radioligand therapy into earlier-line and adjuvant settings 65 5.2.3.3 Combination regimens integrating radioligand therapy 66 5.2.4 CHALLENGES 66 5.2.4.1 Reactor outages and geopolitical risks 66 5.2.4.2 Growing competition from alternative modalities 66 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 67 5.4 PRICING ANALYSIS 68 5.4.1 INDICATIVE PRICING ANALYSIS, BY KEY PLAYER, 2024 68 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION 69 5.5 VALUE CHAIN ANALYSIS 70 5.6 ECOSYSTEM ANALYSIS 71 5.7 INVESTMENT AND FUNDING SCENARIO 73 5.8 TECHNOLOGY ANALYSIS 74 5.8.1 KEY TECHNOLOGIES 74 5.8.1.1 Beta-emitting therapeutic radionuclides 74 5.8.1.2 Alpha-emitting therapeutic radionuclides 74 5.8.1.3 Targeting ligands 74 5.8.1.4 Monoclonal antibody-directed radiotherapeutics 75 5.8.2 COMPLEMENTARY TECHNOLOGIES 75 5.8.2.1 SPECT/CT and PET/CT 75 5.8.2.2 Alternative isotopes 75 5.8.3 ADJACENT TECHNOLOGIES 75 5.8.3.1 Antibody drug conjugates 75 5.8.3.2 Bispecific antibodies 76 5.9 KEY CONFERENCES AND EVENTS, 2025–2027 76 5.10 REGULATORY LANDSCAPE 77 5.10.1 REGULATORY ANALYSIS 77 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 5.11 PORTER’S FIVE FORCES ANALYSIS 81 5.11.1 BARGAINING POWER OF SUPPLIERS 82 5.11.2 BARGAINING POWER OF BUYERS 82 5.11.3 THREAT OF NEW ENTRANTS 82 5.11.4 THREAT OF SUBSTITUTES 82 5.11.5 INTENSITY OF COMPETITIVE RIVALRY 82 5.12 KEY STAKEHOLDERS AND BUYING PROCESS 83 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 83 5.12.2 BUYING CRITERIA 84 5.13 MACROECONOMICS INDICATORS 85 5.13.1 HEALTHCARE EXPENDITURE TRENDS 85 5.13.2 GLOBAL CANCER BURDEN 87 5.14 PIPELINE ANALYSIS 88 5.15 UNMET NEEDS AND WHITE SPACES 89 5.16 IMPACT OF AI/GEN AI ON RADIOLIGAND THERAPY MARKET 90 5.16.1 INTRODUCTION 90 5.16.2 MARKET POTENTIAL OF AI IN RADIOLIGAND THERAPY APPLICATIONS 90 5.16.3 AI USE CASES 91 5.17 IMPACT OF 2025 US TARIFF 92 5.17.1 INTRODUCTION 92 5.17.2 KEY TARIFF RATES 92 5.17.3 PRICE IMPACT ANALYSIS 93 5.17.4 IMPACT ON COUNTRY/REGION 94 5.17.4.1 US 94 5.17.4.2 Europe 94 5.17.4.3 Asia Pacific 95 5.17.4.4 Rest of the World 95 5.17.5 IMPACT ON MANUFACTURING INDUSTRY 96 6 RADIOLIGAND THERAPY MARKET, BY PRODUCT 97 6.1 INTRODUCTION 98 6.2 LUTETIUM 177 VIPIVOTIDE TETRAXETAN 98 6.2.1 BROADER REGULATORY ACCEPTANCE AND EXPANDING PAYER COVERAGE TO AID GROWTH 98 6.3 LUTETIUM-177 DOTATATE 102 6.3.1 INCREASING RECOGNITION OF LUTETIUM-177 DOTATATE IN TREATING GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO BOOST MARKET 102 6.4 RADIUM-223 DICHLORIDE 105 6.4.1 INCREASING ADOPTION OF RADIUM-223 DICHLORIDE IN EMERGING MARKETS TO STIMULATE GROWTH 105 6.5 LU-177 PNT2002 109 6.5.1 STRONG PHASE III CLINICAL VALIDATION AND STRATEGIC COMMERCIALIZATION PARTNERSHIPS TO SPUR GROWH 109 6.6 ²²⁵AC-PSMA-617 112 6.6.1 POTENT THERAPEUTIC PROFILE AND EXPANDING CLINICAL VALIDATION TO BOLSTER GROWTH 112 6.7 FPI-2265 115 6.7.1 EARLY RESPONSE DATA AND SAFETY REASSURANCE TO AMPLIFY GROWTH 115 6.8 I-131-1095 119 6.8.1 FAVORABLE DOSIMETRY AND SAFETY PROFILES TO SUSTAIN GROWTH 119 6.9 TLX591 122 6.9.1 SIMPLIFIED DOSING REGIMEN AND FAVORABLE TOLERABILITY TO DRIVE MARKET 122 6.10 ALPHAMEDIX ( ²¹²PB-DOTAMTATE) 125 6.10.1 ROBUST EARLY-PHASE EFFICACY AND STRONG COMMERCIALIZATION TO SUPPORT GROWTH 125 6.11 67CU-SAR-BISPSMA 129 6.11.1 ENHANCED LESION UPTAKE & RETENTION AND FAVORABLE TOLERABILITY PROFILE TO FOSTER GROWTH 129 6.12 OTHER PRODUCTS 132 7 RADIOLIGAND THERAPY MARKET, BY TARGET 136 7.1 INTRODUCTION 137 7.2 PROSTATE-SPECIFIC MEMBRANE ANTIGEN 137 7.2.1 STRONG BIOLOGICAL RATIONALE, ROBUST CLINICAL OUTCOMES, AND RAPID SCALING OF GLOBAL SUPPLY CHAINS TO PROMOTE GROWTH 137 7.3 SOMATOSTATIN RECEPTOR 141 7.3.1 PROVEN EFFICACY IN TREATING NEUROENDOCRINE TUMORS TO EXPEDITE GROWTH 141 7.4 OTHER TARGETS 144   8 RADIOLIGAND THERAPY MARKET, BY INDICATION 148 8.1 INTRODUCTION 149 8.2 PROSTATE CANCER 149 8.2.1 EXPANDING TREATMENT POPULATIONS AND CLINICAL VALIDATION TO ENCOURAGE GROWTH 149 8.3 NEUROENDOCRINE TUMORS 153 8.3.1 REGULATORY ADVANCEMENTS AND STRATEGIC INDUSTRY MOVES TO FACILITATE GROWTH 153 8.4 OTHER INDICATIONS 156 9 RADIOLIGAND THERAPY MARKET, BY END USER 160 9.1 INTRODUCTION 161 9.2 TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS 161 9.2.1 ADVANCED TREATMENT DELIVERY AND CLINICAL TRIAL CAPABILITIES TO CONTRIBUTE TO GROWTH 161 9.3 SPECIALIZED NUCLEAR MEDICINE CENTERS 165 9.3.1 HIGHLY TRAINED PERSONNEL AND TARGETED FACILITIES TO ACCELERATE GROWTH 165 9.4 OTHER END USERS 169 10 RADIOLIGAND THERAPY MARKET, BY REGION 173 10.1 INTRODUCTION 174 10.2 NORTH AMERICA 174 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 175 10.2.2 US 179 10.2.2.1 Robust ecosystem of biotech innovation and strong academic-industry collaboration to spur growth. 179 10.2.3 CANADA 181 10.2.3.1 Growing clinical trial momentum to drive market 181 10.3 EUROPE 183 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 183 10.3.2 GERMANY 186 10.3.2.1 Strong clinical advancements and active industry partnerships to foster growth. 186 10.3.3 UK 188 10.3.3.1 Growing efforts for decentralized access and innovations to boost market 188 10.3.4 FRANCE 190 10.3.4.1 Strong nuclear medicine manufacturing and isotope supply foundation to bolster growth 190 10.3.5 ITALY 192 10.3.5.1 Rising preclinical exploration and early discovery stages to stimulate growth 192   10.3.6 SPAIN 194 10.3.6.1 Established nuclear-medicine departments and authorized radiopharmacy frameworks to aid growth 194 10.3.7 REST OF EUROPE 196 10.4 ASIA PACIFIC 199 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 199 10.4.2 CHINA 203 10.4.2.1 Favorable regulatory reforms and expanding hospital-based nuclear medicine capabilities to amplify growth 203 10.4.3 JAPAN 205 10.4.3.1 Academic excellence, manufacturing expansion, and supportive regulation to contribute to growth 205 10.4.4 INDIA 207 10.4.4.1 Lower trial costs and skilled medical professionals to accelerate growth 207 10.4.5 SOUTH KOREA 209 10.4.5.1 Growing emphasis on nuclear medicine innovation to propel market 209 10.4.6 AUSTRALIA 211 10.4.6.1 Need to maintain high standards of quality, compliance, and innovation to facilitate growth 211 10.4.7 REST OF ASIA PACIFIC 213 10.5 LATIN AMERICA 215 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 215 10.5.2 BRAZIL 218 10.5.2.1 Favorable educational initiatives and expanding biopharma infrastructure to promote growth 218 10.5.3 MEXICO 220 10.5.3.1 Growing cyclotron capacity to fuel market 220 10.5.4 REST OF LATIN AMERICA 222 10.6 MIDDLE EAST 225 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 225 10.6.2 GCC COUNTRIES 228 10.6.3 SAUDI ARABIA 231 10.6.3.1 Growing initiatives for healthcare and life sciences sectors to drive market 231 10.6.4 UAE 233 10.6.4.1 Emerging biotechnology sector to intensify growth 233 10.6.5 REST OF GCC COUNTRIES 235 10.6.6 REST OF MIDDLE EAST 237 10.7 AFRICA 239 10.7.1 ENHANCED CLINICAL TRIAL ECOSYSTEM AND REGULATORY REFORMS TO AID GROWTH 239 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 239   11 COMPETITIVE LANDSCAPE 242 11.1 INTRODUCTION 242 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 242 11.3 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 242 11.4 REVENUE ANALYSIS, 2028–2030 243 11.5 MARKET SHARE ANALYSIS, 2030 244 11.6 COMPANY VALUATION AND FINANCIAL METRICS 246 11.7 BRAND/PRODUCT COMPARISON 247 11.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 248 11.8.1 STARS 248 11.8.2 EMERGING LEADERS 248 11.8.3 PERVASIVE PLAYERS 248 11.8.4 PARTICIPANTS 248 11.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 250 11.8.5.1 Region footprint 251 11.8.5.2 Target footprint 252 11.8.5.3 Indication footprint 252 11.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 253 11.9.1 PROGRESSIVE COMPANIES 253 11.9.2 RESPONSIVE COMPANIES 253 11.9.3 DYNAMIC COMPANIES 253 11.9.4 STARTING BLOCKS 253 11.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 255 11.9.5.1 Detailed list of key startups/SMEs 255 11.9.5.2 Competitive benchmarking of key startups/SMEs 256 11.10 COMPETITIVE SCENARIO 257 11.10.1 PRODUCT LAUNCHES AND APPROVALS 257 11.10.2 DEALS 258 11.10.3 EXPANSIONS 259 12 COMPANY PROFILES 260 12.1 KEY PLAYERS 260 12.1.1 NOVARTIS AG 260 12.1.1.1 Business overview 260 12.1.1.2 Products offered 261 12.1.1.3 Products in pipeline 262 12.1.1.4 Recent developments 262 12.1.1.4.1 Product launches and approvals 262 12.1.1.4.2 Deals 262 12.1.1.4.3 Expansions 263   12.1.1.5 MnM view 263 12.1.1.5.1 Key strengths 263 12.1.1.5.2 Strategic choices 263 12.1.1.5.3 Weaknesses and competitive threats 264 12.1.2 BAYER AG 265 12.1.2.1 Business overview 265 12.1.2.2 Products offered 266 12.1.2.2.1 Deals 267 12.1.2.2.2 Other developments 267 12.1.2.3 MnM view 267 12.1.2.3.1 Key strengths 267 12.1.2.3.2 Strategic choices 267 12.1.2.3.3 Weaknesses and competitive threats 268 12.1.3 CURIUM US LLC 269 12.1.3.1 Business overview 269 12.1.3.2 Products in pipeline 269 12.1.3.3 Recent developments 269 12.1.3.3.1 Deals 269 12.1.3.4 MnM view 270 12.1.3.4.1 Key strengths 270 12.1.3.4.2 Strategic choices 270 12.1.3.4.3 Weaknesses and competitive threats 270 12.1.4 ELI LILLY AND COMPANY 271 12.1.4.1 Business overview 271 12.1.4.2 Products in pipeline 272 12.1.4.3 Recent developments 273 12.1.4.3.1 Product launches and approvals 273 12.1.4.3.2 Deals 273 12.1.4.4 MnM view 273 12.1.4.4.1 Key strengths 273 12.1.4.4.2 Strategic choices 273 12.1.4.4.3 Weaknesses and competitive threats 274 12.1.5 ASTRAZENECA 275 12.1.5.1 Business overview 275 12.1.5.2 Products in pipeline 276 12.1.5.3 Recent developments 277 12.1.5.3.1 Deals 277 12.1.5.4 MnM view 277 12.1.5.4.1 Key strengths 277 12.1.5.4.2 Strategic choices 277 12.1.5.4.3 Weaknesses and competitive threats 277   12.1.6 PROGENICS PHARMACEUTICALS INC. (LANTHEUS) 278 12.1.6.1 Business overview 278 12.1.6.2 Products in pipeline 279 12.1.6.3 Recent developments 279 12.1.6.3.1 Deals 279 12.1.7 ARICEUM THERAPEUTICS 280 12.1.7.1 Products in pipeline 280 12.1.7.2 Recent developments 280 12.1.7.2.1 Deals 280 12.1.8 TELIX PHARMACEUTICALS 281 12.1.8.1 Business overview 281 12.1.8.2 Products in pipeline 282 12.1.8.3 Recent developments 283 12.1.8.3.1 Deals 283 12.1.8.3.2 Expansions 283 12.1.8.3.3 Other developments 283 12.1.9 ITM ISOTOPE TECHNOLOGIES 284 12.1.9.1 Business overview 284 12.1.9.2 Products offered 284 12.1.9.3 Recent developments 285 12.1.9.3.1 Deals 285 12.1.9.3.2 Expansions 286 12.1.10 CONVERGENT THERAPEUTICS, INC. 287 12.1.10.1 Business overview 287 12.1.10.2 Products in pipeline 287 12.1.10.3 Recent developments 287 12.1.10.3.1 Product launches and approvals 287 12.1.10.3.2 Deals 288 12.1.11 ORANO SA 289 12.1.11.1 Business overview 289 12.1.11.2 Products in pipeline 290 12.1.11.3 Recent developments 291 12.1.11.3.1 Deals 291 12.1.11.3.2 Expansions 291 12.1.12 ACTINIUM PHARMACEUTICALS, INC. 292 12.1.12.1 Business overview 292 12.1.12.2 Products in pipeline 293 12.1.12.3 Recent developments 293 12.1.12.3.1 Product launches and approvals 293 12.1.12.3.2 Deals 293   12.1.13 PERSPECTIVE THERAPEUTICS, INC. 294 12.1.13.1 Business overview 294 12.1.13.2 Products in pipeline 294 12.1.13.3 Recent developments 295 12.1.13.3.1 Deals 295 12.1.14 CLARITY PHARMACEUTICALS 296 12.1.14.1 Business overview 296 12.1.14.2 Products in pipeline 297 12.1.14.3 Recent developments 297 12.1.14.3.1 Deals 297 12.1.14.3.2 Other developments 297 12.1.15 RADIOPHARM THERANOSTICS LTD. 298 12.1.15.1 Business overview 298 12.1.15.2 Products in pipeline 298 12.1.15.3 Recent developments 299 12.1.15.3.1 Deals 299 12.2 OTHER PLAYERS 300 12.2.1 ALPHA 9 ONCOLOGY 300 12.2.2 RATIO THERAPEUTICS 300 12.2.3 NORIA THERAPEUTICS 301 12.2.4 PRECIRIX 301 12.2.5 SOFIE 302 12.2.6 ECKERT & ZIEGLER RADIOPHARMA 302 12.2.7 NORTHSTAR MEDICAL RADIOISOTOPES, LLC 303 12.2.8 IRE- IRE ELIT 303 12.2.9 BWXT MEDICAL LTD. 304 12.2.10 NTP RADIOISOTOPES 304 13 APPENDIX 305 13.1 DISCUSSION GUIDE 305 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 309 13.3 CUSTOMIZATION OPTIONS 311 13.4 RELATED REPORTS 311 13.5 AUTHOR DETAILS 312
圖表清單 List of Tables & Figures
TABLE 1 RADIOLIGAND THERAPY MARKET: INCLUSIONS AND EXCLUSIONS 33 TABLE 2 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 45 TABLE 3 RADIOLIGAND THERAPY MARKET: RISK ANALYSIS 48 TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, FOR RADIOPHARMACEUTICAL MOLECULES BY REGION, 2023–2030 (USD BILLION) 59 TABLE 5 RADIOLIGAND THERAPY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 62 TABLE 6 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024 69 TABLE 7 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY REGION, 2024 70 TABLE 8 RADIOLIGAND THERAPY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 72 TABLE 9 RADIOLIGAND THERAPY MARKET: KEY CONFERENCES AND EVENTS, 2025–2027 76 TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78 TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79 TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80 TABLE 14 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81 TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS (%) 83 TABLE 16 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY, BY END USER 84 TABLE 17 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 86 TABLE 18 US: CANCER INCIDENCE, BY STATE, 2024 87 TABLE 19 RADIOLIGAND THERAPY PRODUCTS IN CLINICAL PIPELINE, 2025–2032 88 TABLE 20 US-ADJUSTED RECIPROCAL TARIFF RATES 92 TABLE 21 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 98 TABLE 22 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION) 99 TABLE 23 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 99 TABLE 24 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 100 TABLE 25 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 100 TABLE 26 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 101 TABLE 27 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY REGION, 2023–2035 (USD MILLION) 101 TABLE 28 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 VIPIVOTIDE TETRAXETAN, BY COUNTRY, 2023–2035 (USD MILLION) 101 TABLE 29 RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION) 102 TABLE 30 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 103 TABLE 31 EUROPE: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 103 TABLE 32 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 104 TABLE 33 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 104 TABLE 34 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY REGION, 2023–2035 (USD MILLION) 104 TABLE 35 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LUTETIUM-177 DOTATATE, BY COUNTRY, 2023–2035 (USD MILLION) 105 TABLE 36 RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION) 106 TABLE 37 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 106 TABLE 38 EUROPE: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 107 TABLE 39 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 107 TABLE 40 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108 TABLE 41 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY REGION, 2023–2035 (USD MILLION) 108 TABLE 42 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR RADIUM-223 DICHLORIDE, BY COUNTRY, 2023–2035 (USD MILLION) 108 TABLE 43 RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION) 109 TABLE 44 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 109 TABLE 45 EUROPE: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 110 TABLE 46 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 110 TABLE 47 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 48 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY REGION, 2023–2035 (USD MILLION) 111 TABLE 49 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR LU-177 PNT2002, BY COUNTRY, 2023–2035 (USD MILLION) 111 TABLE 50 RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION) 112 TABLE 51 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION) 113 TABLE 52 EUROPE: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION) 113 TABLE 53 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION) 114 TABLE 54 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617,0 BY COUNTRY, 2023–2035 (USD MILLION) 114 TABLE 55 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY REGION, 2023–2035 (USD MILLION) 114 TABLE 56 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²²⁵AC-PSMA-617, BY COUNTRY, 2023–2035 (USD MILLION) 115 TABLE 57 RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION) 116 TABLE 58 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 116 TABLE 59 EUROPE: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 60 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 117 TABLE 61 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 118 TABLE 62 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY REGION, 2023–2035 (USD MILLION) 118 TABLE 63 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR FPI-2265, BY COUNTRY, 2023–2035 (USD MILLION) 118 TABLE 64 RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION) 119 TABLE 65 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 119 TABLE 66 EUROPE: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 67 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 120 TABLE 68 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 121 TABLE 69 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY REGION, 2023–2035 (USD MILLION) 121 TABLE 70 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR I-131-1095, BY COUNTRY, 2023–2035 (USD MILLION) 121 TABLE 71 RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION) 122 TABLE 72 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 123 TABLE 73 EUROPE: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 123 TABLE 74 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 124 TABLE 75 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 124 TABLE 76 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TLX591, BY REGION, 2023–2035 (USD MILLION) 124 TABLE 77 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TLX591, BY COUNTRY, 2023–2035 (USD MILLION) 125 TABLE 78 RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION) 126 TABLE 79 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 126 TABLE 80 EUROPE: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 81 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 127 TABLE 82 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 83 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY REGION, 2023–2035 (USD MILLION) 128 TABLE 84 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR ²¹²PB-DOTAMTATE, BY COUNTRY, 2023–2035 (USD MILLION) 128 TABLE 85 RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION) 129 TABLE 86 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 130 TABLE 87 EUROPE: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 130 TABLE 88 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 89 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 131 TABLE 90 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY REGION, 2023–2035 (USD MILLION) 131 TABLE 91 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR 67CU-SAR-BISPSMA, BY COUNTRY, 2023–2035 (USD MILLION) 132 TABLE 92 RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION) 132 TABLE 93 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 94 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 133 TABLE 95 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 96 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 134 TABLE 97 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2035 (USD MILLION) 134 TABLE 98 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2035 (USD MILLION) 135 TABLE 99 RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 137 TABLE 100 RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION) 138 TABLE 101 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 138 TABLE 102 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 139 TABLE 103 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 139 TABLE 104 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 140 TABLE 105 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY REGION, 2023–2035 (USD MILLION) 140 TABLE 106 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE-SPECIFIC MEMBRANE ANTIGEN, BY COUNTRY, 2023–2035 (USD MILLION) 140 TABLE 107 RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION) 141 TABLE 108 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 142 TABLE 109 EUROPE: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 142 TABLE 110 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 143 TABLE 111 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 143 TABLE 112 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY REGION, 2023–2035 (USD MILLION) 143 TABLE 113 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SOMATOSTATIN RECEPTOR, BY COUNTRY, 2023–2035 (USD MILLION) 144 TABLE 114 RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION) 145 TABLE 115 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION) 145 TABLE 116 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION) 146 TABLE 117 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION) 146 TABLE 118 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY COUNTRY, 2023–2035 (USD MILLION) 147 TABLE 119 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION) 147 TABLE 120 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER TARGETS, BY REGION, 2023–2035 (USD MILLION) 147 TABLE 121 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 149 TABLE 122 RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION) 150 TABLE 123 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 150 TABLE 124 EUROPE: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 125 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 151 TABLE 126 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 152 TABLE 127 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY REGION, 2023–2035 (USD MILLION) 152 TABLE 128 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2035 (USD MILLION) 152 TABLE 129 RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION) 153 TABLE 130 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 154 TABLE 131 EUROPE: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 154 TABLE 132 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 155 TABLE 133 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 155 TABLE 134 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY REGION, 2023–2035 (USD MILLION) 155 TABLE 135 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR NEUROENDOCRINE TUMORS, BY COUNTRY, 2023–2035 (USD MILLION) 156 TABLE 136 RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION) 156 TABLE 137 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 157 TABLE 138 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 157 TABLE 139 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 158 TABLE 140 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 158 TABLE 141 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION) 158 TABLE 142 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 159 TABLE 143 RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 161 TABLE 144 RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION) 162 TABLE 145 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 162 TABLE 146 EUROPE: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 163 TABLE 147 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 163 TABLE 148 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 164 TABLE 149 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY REGION, 2023–2035 (USD MILLION) 164 TABLE 150 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR TERTIARY CARE ACADEMIC/COMPREHENSIVE CANCER CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 165 TABLE 151 RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION) 166 TABLE 152 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 166 TABLE 153 EUROPE: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 167 TABLE 154 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 167 TABLE 155 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 168 TABLE 156 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY REGION, 2023–2035 (USD MILLION) 168 TABLE 157 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR SPECIALIZED NUCLEAR MEDICINE CENTERS, BY COUNTRY, 2023–2035 (USD MILLION) 168 TABLE 158 RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION) 169 TABLE 159 NORTH AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 170 TABLE 160 EUROPE: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 170 TABLE 161 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 171 TABLE 162 LATIN AMERICA: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 171 TABLE 163 MIDDLE EAST: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY REGION, 2023–2035 (USD MILLION) 171 TABLE 164 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2035 (USD MILLION) 172 TABLE 165 RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION) 174 TABLE 166 NORTH AMERICA: KEY MACROECONOMIC INDICATORS 176 TABLE 167 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 177 TABLE 168 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 177 TABLE 169 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 178 TABLE 170 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 178 TABLE 171 NORTH AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 178 TABLE 172 US: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 179 TABLE 173 US: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 180 TABLE 174 US: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 180 TABLE 175 US: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 180 TABLE 176 CANADA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 181 TABLE 177 CANADA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 182 TABLE 178 CANADA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 182 TABLE 179 CANADA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 182 TABLE 180 EUROPE: KEY MACROECONOMIC INDICATORS 184 TABLE 181 EUROPE: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 184 TABLE 182 EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 185 TABLE 183 EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 185 TABLE 184 EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 186 TABLE 185 EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 186 TABLE 186 GERMANY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 187 TABLE 187 GERMANY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 187 TABLE 188 GERMANY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 188 TABLE 189 GERMANY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 188 TABLE 190 UK: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 189 TABLE 191 UK: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 189 TABLE 192 UK: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 190 TABLE 193 UK: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 190 TABLE 194 FRANCE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 191 TABLE 195 FRANCE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 191 TABLE 196 FRANCE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 192 TABLE 197 FRANCE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 192 TABLE 198 ITALY: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 193 TABLE 199 ITALY: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 193 TABLE 200 ITALY: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 194 TABLE 201 ITALY: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 194 TABLE 202 SPAIN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 195 TABLE 203 SPAIN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 195 TABLE 204 SPAIN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 196 TABLE 205 SPAIN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 196 TABLE 206 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 197 TABLE 207 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 197 TABLE 208 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 198 TABLE 209 REST OF EUROPE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 198 TABLE 210 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS 200 TABLE 211 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 201 TABLE 212 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 201 TABLE 213 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 202 TABLE 214 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 202 TABLE 215 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 202 TABLE 216 CHINA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 203 TABLE 217 CHINA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 204 TABLE 218 CHINA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 204 TABLE 219 CHINA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 204 TABLE 220 JAPAN: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 205 TABLE 221 JAPAN: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 206 TABLE 222 JAPAN: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 206 TABLE 223 JAPAN: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 206 TABLE 224 INDIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 207 TABLE 225 INDIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 208 TABLE 226 INDIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 208 TABLE 227 INDIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 208 TABLE 228 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 209 TABLE 229 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 210 TABLE 230 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 210 TABLE 231 SOUTH KOREA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 210 TABLE 232 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 211 TABLE 233 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 212 TABLE 234 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 212 TABLE 235 AUSTRALIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 212 TABLE 236 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 213 TABLE 237 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 214 TABLE 238 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 214 TABLE 239 REST OF ASIA PACIFIC: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 214 TABLE 240 LATIN AMERICA: KEY MACROECONOMIC INDICATORS 216 TABLE 241 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 216 TABLE 242 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 217 TABLE 243 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 217 TABLE 244 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 218 TABLE 245 LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 218 TABLE 246 BRAZIL: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 219 TABLE 247 BRAZIL: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 219 TABLE 248 BRAZIL: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 220 TABLE 249 BRAZIL: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 220 TABLE 250 MEXICO: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 221 TABLE 251 MEXICO: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 221 TABLE 252 MEXICO: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 222 TABLE 253 MEXICO: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 222 TABLE 254 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 223 TABLE 255 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 223 TABLE 256 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 224 TABLE 257 REST OF LATIN AMERICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 224 TABLE 258 MIDDLE EAST: KEY MACROECONOMIC INDICATORS 226 TABLE 259 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY REGION, 2023–2035 (USD MILLION) 226 TABLE 260 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 227 TABLE 261 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 227 TABLE 262 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 228 TABLE 263 MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 228 TABLE 264 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 229 TABLE 265 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 229 TABLE 266 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 230 TABLE 267 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 230 TABLE 268 GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 230 TABLE 269 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 231 TABLE 270 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 232 TABLE 271 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 232 TABLE 272 SAUDI ARABIA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 232 TABLE 273 UAE: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 233 TABLE 274 UAE: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 234 TABLE 275 UAE: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 234 TABLE 276 UAE: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 234 TABLE 277 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 235 TABLE 278 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 236 TABLE 279 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 236 TABLE 280 REST OF GCC COUNTRIES: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 236 TABLE 281 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 237 TABLE 282 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 238 TABLE 283 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 238 TABLE 284 REST OF MIDDLE EAST: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 238 TABLE 285 AFRICA: KEY MACROECONOMIC INDICATORS 240 TABLE 286 AFRICA: RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2023–2035 (USD MILLION) 240 TABLE 287 AFRICA: RADIOLIGAND THERAPY MARKET, BY TARGET, 2023–2035 (USD MILLION) 241 TABLE 288 AFRICA: RADIOLIGAND THERAPY MARKET, BY INDICATION, 2023–2035 (USD MILLION) 241 TABLE 289 AFRICA: RADIOLIGAND THERAPY MARKET, BY END USER, 2023–2035 (USD MILLION) 241 TABLE 290 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOLIGAND THERAPY MARKET, 2023–2025 242 TABLE 291 RADIOLIGAND THERAPY MARKET: DEGREE OF COMPETITION 245 TABLE 292 RADIOLIGAND THERAPY MARKET: REGION FOOTPRINT 251 TABLE 293 RADIOLIGAND THERAPY MARKET: TARGET FOOTPRINT 252 TABLE 294 RADIOLIGAND THERAPY MARKET: INDICATION FOOTPRINT 252 TABLE 295 RADIOLIGAND THERAPY MARKET: DETAILED LIST OF KEY STARTUPS/SMES 255 TABLE 296 RADIOLIGAND THERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 256 TABLE 297 RADIOLIGAND THERAPY MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 257 TABLE 298 RADIOLIGAND THERAPY MARKET: DEALS, JANUARY 2022–AUGUST 2025 258 TABLE 299 RADIOLIGAND THERAPY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025 259 TABLE 300 NOVARTIS AG: COMPANY OVERVIEW 260 TABLE 301 NOVARTIS AG: PRODUCTS OFFERED 261 TABLE 302 NOVARTIS AG: PRODUCTS IN PIPELINE 262 TABLE 303 NOVARTIS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 262 TABLE 304 NOVARTIS AG: DEALS, JANUARY 2022–AUGUST 2025 262 TABLE 305 NOVARTIS AG: EXPANSIONS, JANUARY 2022–AUGUST 2025 263 TABLE 306 BAYER AG: COMPANY OVERVIEW 265 TABLE 307 BAYER AG: PRODUCTS OFFERED 266 TABLE 308 BAYER AG: DEALS, JANUARY 2022–AUGUST 2025 267 TABLE 309 BAYER AG: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 267 TABLE 310 CURIUM US LLC: COMPANY OVERVIEW 269 TABLE 311 CURIUM US LLC: PRODUCTS IN PIPELINE 269 TABLE 312 CURIUM US LLC: DEALS, JANUARY 2022–AUGUST 2025 269 TABLE 313 ELI LILLY AND COMPANY: COMPANY OVERVIEW 271 TABLE 314 ELI LILLY AND COMPANY: PRODUCTS IN PIPELINE 272 TABLE 315 ELI LILLY AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022– AUGUST 2025 273 TABLE 316 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–AUGUST 2025 273 TABLE 317 ASTRAZENECA: COMPANY OVERVIEW 275 TABLE 318 ASTRAZENECA: PRODUCTS IN PIPELINE 276 TABLE 319 ASTRAZENECA: DEALS, JANUARY 2022–AUGUST 2025 277 TABLE 320 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY OVERVIEW 278 TABLE 321 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): PRODUCTS IN PIPELINE 279 TABLE 322 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): DEALS, JANUARY 2022–AUGUST 2025 279 TABLE 323 ARICEUM THERAPEUTICS: COMPANY OVERVIEW 280 TABLE 324 ARICEUM THERAPEUTICS: PRODUCTS IN PIPELINE 280 TABLE 325 ARICEUM THERAPEUTICS: DEALS, JANUARY 2022–AUGUST 2025 280 TABLE 326 TELIX PHARMACEUTICALS: COMPANY OVERVIEW 281 TABLE 327 TELIX PHARMACEUTICALS: PRODUCTS IN PIPELINE 282 TABLE 328 TELIX PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025 283 TABLE 329 TELIX PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–AUGUST 2025 283 TABLE 330 TELIX PHARMACEUTICAL: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 283 TABLE 331 ITM ISOTOPE TECHNOLOGIES: COMPANY OVERVIEW 284 TABLE 332 ITM ISOTOPE TECHNOLOGIES: PRODUCTS OFFERED 284 TABLE 333 ITM ISOTOPE TECHNOLOGIES: DEALS, JANUARY 2022–AUGUST 2025 285 TABLE 334 ITM ISOTOPE TECHNOLOGIES: EXPANSIONS, JANUARY 2022–AUGUST 2025 286 TABLE 335 CONVERGENT THERAPEUTICS, INC.: COMPANY OVERVIEW 287 TABLE 336 CONVERGENT THERAPEUTICS, INC.: PRODUCTS IN PIPELINE 287 TABLE 337 CONVERGENT THERAPEUTICS, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 287 TABLE 338 CONVERGENT THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025 288 TABLE 339 ORANO SA: COMPANY OVERVIEW 289 TABLE 340 ORANO SA: PRODUCTS IN PIPELINE 290 TABLE 341 ORANO SA: DEALS, JANUARY 2022–AUGUST 2025 291 TABLE 342 ORANO SA: EXPANSIONS, JANUARY 2022–AUGUST 2025 291 TABLE 343 ACTINIUM PHARMACEUTICALS, INC.: COMPANY OVERVIEW 292 TABLE 344 ACTINIUM PHARMACEUTICALS, INC.: PRODUCTS IN PIPELINE 293 TABLE 345 ACTINIUM PHARMACEUTICALS, INC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–AUGUST 2025 293 TABLE 346 ACTINIUM PHARMACEUTICALS, INC.: DEALS, JANUARY 2022–AUGUST 2025 293 TABLE 347 PERSPECTIVE THERAPEUTICS, INC.: COMPANY OVERVIEW 294 TABLE 348 PERSPECTIVE THERAPEUTICS, INC.: PRODUCTS IN PIPELINE 294 TABLE 349 PERSPECTIVE THERAPEUTICS, INC.: DEALS, JANUARY 2022–AUGUST 2025 295 TABLE 350 CLARITY PHARMACEUTICALS: COMPANY OVERVIEW 296 TABLE 351 CLARITY PHARMACEUTICALS: PRODUCTS IN PIPELINE 297 TABLE 352 CLARITY PHARMACEUTICALS: DEALS, JANUARY 2022–AUGUST 2025 297 TABLE 353 CLARITY PHARMACEUTICALS: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025 297 TABLE 354 RADIOPHARM THERANOSTICS LTD.: COMPANY OVERVIEW 298 TABLE 355 RADIOPHARM THERANOSTICS LTD.: PRODUCTS IN PIPELINE 298 TABLE 356 RADIOPHARM THERANOSTICS LTD.: DEALS, JANUARY 2022–AUGUST 2025 299 TABLE 357 ALPHA 9 ONCOLOGY: COMPANY OVERVIEW 300 TABLE 358 RATIO THERAPEUTICS: COMPANY OVERVIEW 300 TABLE 359 NORIA THERAPEUTICS: COMPANY OVERVIEW 301 TABLE 360 PRECIRIX: COMPANY OVERVIEW 301 TABLE 361 SOFIE: COMPANY OVERVIEW 302 TABLE 362 ECKERT & ZIEGLER RADIOPHARMA: COMPANY OVERVIEW 302 TABLE 363 NORTHSTAR MEDICAL RADIOISOTOPES, LLC: COMPANY OVERVIEW 303 TABLE 364 IRE- IRE ELIT: COMPANY OVERVIEW 303 TABLE 365 BWXT MEDICAL LTD.: COMPANY OVERVIEW 304 TABLE 366 NTP RADIOISOTOPES: COMPANY OVERVIEW 304 FIGURE 1 RADIOLIGAND THERAPY MARKET SEGMENTATION AND REGIONAL SCOPE 32 FIGURE 2 RADIOLIGAND THERAPY MARKET: YEARS CONSIDERED 33 FIGURE 3 RADIOLIGAND THERAPY MARKET: RESEARCH DESIGN 35 FIGURE 4 RADIOLIGAND THERAPY MARKET: KEY DATA FROM SECONDARY SOURCES 37 FIGURE 5 RADIOLIGAND THERAPY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38 FIGURE 6 RADIOLIGAND THERAPY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 39 FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH, 2030 40 FIGURE 8 REVENUE SHARE ANALYSIS OF NOVARTIS, 2024 40 FIGURE 9 RADIOLIGAND THERAPY MARKET SIZE VALIDATION FROM PRIMARY SOURCES 42 FIGURE 10 RADIOLIGAND THERAPY MARKET: TOP-DOWN APPROACH 43 FIGURE 11 RADIOLIGAND THERAPY MARKET: CAGR PROJECTIONS 44 FIGURE 12 RADIOLIGAND THERAPY MARKET: DATA TRIANGULATION 46 FIGURE 13 RADIOLIGAND THERAPY MARKET: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 FIGURE 14 RADIOLIGAND THERAPY MARKET, BY PRODUCT, 2025 VS. 2035 (USD MILLION) 51 FIGURE 15 RADIOLIGAND THERAPY MARKET, BY TARGET, 2025 VS. 2035 (USD MILLION) 52 FIGURE 16 RADIOLIGAND THERAPY MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION) 52 FIGURE 17 RADIOLIGAND THERAPY MARKET, BY END USER, 2025 VS. 2035 (USD MILLION) 53 FIGURE 18 GEOGRAPHICAL SNAPSHOT OF RADIOLIGAND THERAPY MARKET 54 FIGURE 19 INCREASING APPROVALS AND LABEL EXPANSION OF RLT PRODUCTS TO DRIVE MARKET 55 FIGURE 20 LUTETIUM‑177 VIPIVOTIDE TETRAXETAN SEGMENT AND US TO LEAD NORTH AMERICAN MARKET IN 2024 56 FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 57 FIGURE 22 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 58 FIGURE 23 RADIOLIGAND THERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61 FIGURE 24 NEW REVENUE POCKETS FOR PLAYERS IN RADIOLIGAND THERAPY MARKET 67 FIGURE 25 INDICATIVE PRICING ANALYSIS OF RADIOLIGAND THERAPY PRODUCTS, BY KEY PLAYER, 2024 68 FIGURE 26 INDICATIVE PRICING ANALYSIS, BY REGION, 2024 69 FIGURE 27 RADIOLIGAND THERAPY MARKET: VALUE CHAIN ANALYSIS 70 FIGURE 28 RADIOLIGAND THERAPY MARKET: ECOSYSTEM ANALYSIS 72 FIGURE 29 RADIOLIGAND THERAPY MARKET: INVESTMENT AND FUNDING SCENARIO, 2023–2024 73 FIGURE 30 RADIOLIGAND THERAPY MARKET: PORTER’S FIVE FORCES ANALYSIS 81 FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOLIGAND THERAPY PRODUCTS 83 FIGURE 32 KEY BUYING CRITERIA FOR RADIOLIGAND THERAPY PRODUCTS, BY END USER 84 FIGURE 33 RADIOLIGAND THERAPY MARKET: AI USE CASES 91 FIGURE 34 NORTH AMERICA: RADIOLIGAND THERAPY MARKET SNAPSHOT 176 FIGURE 35 ASIA PACIFIC: RADIOLIGAND THERAPY MARKET SNAPSHOT 200 FIGURE 36 RADIOLIGAND THERAPY MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2028–2030 (USD MILLION) 244 FIGURE 37 RADIOLIGAND THERAPY MARKET SHARE ANALYSIS OF KEY PLAYERS, 2030 245 FIGURE 38 EV/EBITDA OF KEY VENDORS 246 FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 247 FIGURE 40 RADIOLIGAND THERAPY MARKET: BRAND/PRODUCT COMPARISON 247 FIGURE 41 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 249 FIGURE 42 RADIOLIGAND THERAPY MARKET: COMPANY FOOTPRINT 250 FIGURE 43 RADIOLIGAND THERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 254 FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024) 261 FIGURE 45 BAYER AG: COMPANY SNAPSHOT (2024) 266 FIGURE 46 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2024) 272 FIGURE 47 ASTRAZENECA: COMPANY SNAPSHOT (2024) 276 FIGURE 48 PROGENICS PHARMACEUTICAL INC. (LANTHEUS): COMPANY SNAPSHOT (2024) 278 FIGURE 49 TELIX PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 282 FIGURE 50 ORANO SA: COMPANY SNAPSHOT (2024) 290 FIGURE 51 ACTINIUM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023) 292 FIGURE 52 CLARITY PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 296

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們